Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
announced that members of the Company will present at multiple upcoming
scientific and investor conferences. The Verastem presentation
information is as follows:
Advances in Ovarian Cancer Research: From Concept
to Clinic Conference
Date: September 18-21, 2013 at
the J.W. Marriott Marquis in Miami, FL
Presentation 1:
|
|
Title:
|
FAK inhibitors VS-6063 and VS-4718 preferentially target ovarian
cancer stem cells
|
Session:
|
Poster Session A, Thursday, September 19, 4:30 p.m. – 6:30 p.m.
|
Location:
|
Met Ballroom 2-4, Met Ballroom 5-7
|
Abstract:
|
A39
|
Presentation 2:
|
|
Title:
|
Predictive biomarkers for FAK inhibitor sensitivity in ovarian cancer
|
Session:
|
Poster Session B, Friday, September 20, 12:30 p.m. – 2:30 p.m.
|
Location:
|
Met Ballroom 2-4, Met Ballroom 5-7
|
Abstract:
|
B13
|
Cancer Advance at Harvard Medical
Date:
September 19, 2013 at Harvard Medical School in Boston, MA
Summary: Verastem executives will join panel discussions
throughout the day, addressing industry leaders from Eli Lilly, Harvard
University, Johnson & Johnson, Mass General Hospital, and Pfizer among
others. President and CEO Robert Forrester will moderate the
investor-focused panel “Betting on Oncology: Investor Perspectives” and
Chief Business Officer Dan Paterson will join colleagues to discuss
efficacy and pricing issues on the “Regulatory and Reimbursement
Pressures for Cancer Drugs” panel. Chief Medical Officer Joanna Horobin
and Head of Research Jonathan Pachter will also address the audience in
two Q&A discussions that will focus on clinical trials in oncology. In
addition, Verastem will also be presenting two trials in progress
posters describing the registration-directed COMMAND study in
mesothelioma and the ongoing combination study of paclitaxel and
defactinib in patients with ovarian cancer.
Joint MipTec / BioValley Keynote Address
Date:
September 24, 2013 at 1:40 p.m. CET at the Congress Center Basel, in
Basel, Switzerland
Presenter: Christoph Westphal, M.D., Ph.D., Verastem Executive
Chairman
Title: “Drug Innovation in Biotech: Alnylam, Momenta, Sirtris,
Verastem”
Summary: Dr. Christoph Westphal is delivering the keynote address
to the MipTec conference in Basel. In 2012 the keynote was presented by
the Head of Research and Development at Regeneron, Dr. George
Yancopoulos. This year’s keynote by Dr. Westphal will describe how over
the last 13 years, discoveries at MIT and Harvard have been turned into
several public biotechnology companies, valued at several hundred
million, to several billion in market capitalization. In each case, the
team has been motivated by a desire to develop important new medicines
for patients with serious illnesses. Working with great people, on
fundamentally important novel science, with the chance to make
transformative medicines can, if you are lucky, also create value for
shareholders. Some of these unifying themes and learnings are captured
in briefly describing the similar, and divergent, paths of four
companies Dr. Westphal has founded as CEO: Alnylam, Momenta, Sirtris,
and Verastem.
BioCentury’s 2013 Newsmakers in the Biotech
Industry Conference
Date: September 27, 2013 at 9:30
a.m. ET at the Millennium Broadway Hotel in New York, NY
Webcast: A webcast of the Newsmakers presentation can be accessed
by visiting the investors section of the Company’s website at www.verastem.com.
A replay of the webcast will be archived on the Verastem website for 30
days following the presentation date.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to
treat cancer by the targeted killing of cancer
stem cells. Cancer stem cells are an underlying cause of tumor
recurrence and metastasis. Verastem is developing small molecule
inhibitors of signaling pathways that are critical to cancer stem cell
survival and proliferation: FAK, PI3K/mTOR and Wnt. For more
information, please visit www.verastem.com.
Forward-looking statements:
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements.
Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Copyright Business Wire 2013